Effect of outpatient treatment of febrile neutropenia on the risk threshold for the use of CSF in patients with cancer treated with chemotherapy

Value in Health

Volumn 8, Issue 1, 2005, Pages 47-52

  Cosler, Leon E ^a,b   Sivasubramaniam, Visaharan ^c   Agboola, Olayemi ^b   Crawford, Jeffrey ^d   Dale, David ^e   Lyman, Gary H ^b  

^a ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^c UNIVERSITY OF KENTUCKY MEDICAL CENTER   (United States)

^d DUKE UNIVERSITY   (United States)

^e UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Cost minimization; Febrile neutropenia; Growth factors; Neutropenia; Outpatient; Pharmacoeconomics; Risk model

Indexed keywords

ANTIBIOTIC AGENT; COLONY STIMULATING FACTOR;

ARTICLE; CANCER CHEMOTHERAPY; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG USE; FEBRILE NEUTROPENIA; HOSPITAL COST; HOSPITALIZATION; HUMAN; INFECTION; LENGTH OF STAY; MAJOR CLINICAL STUDY; NEUTROPENIA; OUTPATIENT CARE; PRIORITY JOURNAL; PROPHYLAXIS; RISK FACTOR; TREATMENT OUTCOME;

EID: 14344257999     PISSN: 10983015     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1524-4733.2005.03099.x     Document Type: Article

References (19)

1. Pizzo PA, Hathorn JW, Heimenz J, et al. A randomized trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with neutropenia and fever. N Engl J Med 1986;315:552-8.
2. Groopman JE, Molina JM, Scadden DT. Hematopoietic growth factors. Biology and clinical application. N Engl J Med 1989;321:1449-59.
3. Welte K, Gabrilove J, Bronchud MH, et al. Filgrastim (r-metHuCSF): the first 10 years. Blood 1996;88:1907-29.
4. Johnsen HE. Clinical practice and future needs in recombinant human granulocyte colony-stimulating factor treatment: a review of randomized trials in clinical haemato-oncology. J Int Med Res 2001;29:87-99.
5. Lyman GH, Kuderer N, Greene J, Balducci L. The economics of febrile neutropenia. Implications for the use of colony-stimulating factors. Eur J Cancer 1998;34:1857-64.
6. Lyman GH, Kuderer NM, Djulbegovic B. Prophylactic granulocyte colony-stimulating factor in patients receiving dose-intensive cancer chemotherapy: a meta-analysis. Am J Med 2002;112:406-11.
7. Lyman GH, Lyman CG, Sanderson RA, Balducci L. Decision analysis of hematopoietic growth factor use in patients receiving cancer chemotherapy. J Natl Cancer Inst 1993;85:488-93.
8. Ozer H. American Society of Clinical Oncology guidelines for the use of hematopoietic colonystimulating factors. Curr Opin Hematol 1996;3:3-10.
9. Lyman GH, Kuderer NM, Balducci L. Economic impact of granulopoiesis stimulating agents on the management of febrile neutropenia. Curr Opin Oncol 1998;10:291-6.
10. Lyman GH. A predictive model for neutropenia associated with cancer chemotherapy. Pharmacotherapy 2000;20:104S-11S.
11. Cosler LE, Calhoun EA, Agboola O, Lyman GH. Effects of indirect and additional direct costs on the risk threshold for prophylaxis with colony-stimulating factors in patients at risk for severe neutropenia from cancer chemotherapy. Pharmacotherapy 2004;24:488-94.
12. Garcia-Carbonero R, Paz-Ares L. Antibiotics and growth factors in the management of fever and neutropenia in cancer patients. Curr Opin Hematol 2002;9:215-21.
13. Rolston KV. New trends in patient management: risk-based therapy for febrile patients with neutropenia. Clin Infect Dis 1999;29:515-21.
14. Talcott JA. Out-patient management of febrile neutropenia. Int J Antimicrob Agents 2000;16: 169-71.
15. Klastersky J, Paesmans M, Rubinstein EB, et al. The Multinational Association for Supportive Care in Cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 2000; 18:3038-51.
16. Talcott JA, Siegel RD, Finberg R, Goldman L. Risk assessment in cancer patients with fever and neutropenia: a prospective, two-center validation of a prediction rule. J Clin Oncol 1992;10:316-22.
17. Crawford J, Ozer H, Stoller R, et al. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 1991;325:164-70.
18. Kuderer N, Cosler LE, Crawford J, Dale DC, Lyman GH. Cost and mortality associated with febrile neutropenia in adult cancer patients. Proc Am Soc Clin Oncol 2002;21:250a. Abstract 998.
19. Ozer H, Armitage JO, Bennett CL, et al. 2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. J Clin Oncol 2000;18:3558-85.